Drug · CHEMBL98

VORINOSTAT

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. VORINOSTAT. Drugs and targets, record CHEMBL98. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL98

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: VORINOSTAT; ChEMBL
ChEMBL ID: CHEMBL98; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Zolinza; ChEMBL
Other names: MK-0683, MK0683, NSC-701852, NSC-748799, NSC-759852, Suberoylanilide hydroxamic acid; ChEMBL
DrugBank: DB02546; DrugBank
InChIKey: WAEXFXRVDQXREF-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 3 of its 123 diseases, from ATC, DailyMed, PMDA and TTD; Open Targets

Targets4

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
HDAC1	Histone deacetylase 1	Histone deacetylase 1 inhibitor	INHIBITOR	https://conductscience.org/library/genes/3065
HDAC2	Histone deacetylase 2	Histone deacetylase 2 inhibitor	INHIBITOR	https://conductscience.org/library/genes/3066
HDAC3	Histone deacetylase 3	Histone deacetylase 3 inhibitor	INHIBITOR	https://conductscience.org/library/genes/8841
HDAC6	Protein deacetylase HDAC6	Histone deacetylase 6 inhibitor	INHIBITOR	https://conductscience.org/library/genes/10013

Source ChEMBL

Diseases123

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
acute myeloid leukemia	Phase 3	ClinicalTrials.gov	21	21	https://conductscience.org/library/drugs?q=MONDO_0018874
non-small cell lung carcinoma	Phase 2/3	ClinicalTrials.gov	21	21	https://conductscience.org/library/drugs?q=MONDO_0005233
plasma cell myeloma	Phase 3	ClinicalTrials.gov	21	21	https://conductscience.org/library/drugs?q=MONDO_0009693
breast cancer	Phase 2	ClinicalTrials.gov	19	19	https://conductscience.org/library/drugs?q=MONDO_0007254
myelodysplastic syndrome	Phase 2	ClinicalTrials.gov	17	17	https://conductscience.org/library/drugs?q=MONDO_0018881
lymphoma	Phase 1/2	ClinicalTrials.gov	16	16	https://conductscience.org/library/drugs?q=MONDO_0005062
diffuse large B-cell lymphoma	Phase 2	ClinicalTrials.gov	12	12	https://conductscience.org/library/drugs?q=MONDO_0018905
primary cutaneous T-cell non-Hodgkin lymphoma	Approval	DailyMed, PMDA and TTD	14	11	https://conductscience.org/library/drugs?q=MONDO_0000607
acute lymphoblastic leukemia	Phase 2/3	ClinicalTrials.gov	11	11	https://conductscience.org/library/drugs?q=MONDO_0004967
glioblastoma	Phase 2/3	ClinicalTrials.gov	11	11	https://conductscience.org/library/drugs?q=MONDO_0018177

1 to 10 of 123Source Open Targets

See all 123 diseases

Trials282

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01802333	Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia	Phase 3	754	2018-12-19	vorinostat	Its name	ClinicalTrials.gov
NCT00128102	Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)	Phase 3	661	2020-10-26	vorinostat	Its name	ClinicalTrials.gov
NCT00773747	Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)	Phase 3	637	2021-04-30	vorinostat	Its name	ClinicalTrials.gov
NCT01728805	Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL	Phase 3	372	2019-04-11	vorinostat	Its name	ClinicalTrials.gov
NCT00703820	Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia	Phase 3	324	2018-04-02	vorinostat	Its name	ClinicalTrials.gov
NCT01522976	Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia	Phase 2	282	2016-03-22	vorinostat	Its name	ClinicalTrials.gov
NCT00473889	A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)	Phase 2/3	253	2009-10-12	vorinostat	Its name	ClinicalTrials.gov
NCT00773838	Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)	Phase 2	143	2021-04-01	vorinostat	Its name	ClinicalTrials.gov
NCT00731731	Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	Phase 1/2	125	2015-05-13	vorinostat	Its name	ClinicalTrials.gov
NCT02638090	Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)	Phase 1/2	120	2025-05-04	vorinostat	Its name	ClinicalTrials.gov

1 to 10 of 282

See all 282 trials

Comparisons in its trials76

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Vorinostat vs Placebo: deaths from any cause	288 of 329	284 of 332	661	NCT00128102	Trial comparisons
Vorinostat vs Placebo: Number of Participants Who Experienced Adverse Events (AEs) Characterized as Grade 3 or Grade 4 According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)	165 of 329	146 of 329	658	NCT00128102	Trial comparisons
Vorinostat vs Placebo: Number of Participants Who Experienced an AE	327 of 329	311 of 329	658	NCT00128102	Trial comparisons
Vorinostat vs Placebo: Number of Participants Who Discontinued Study Treatment Due to an AE	60 of 329	49 of 329	658	NCT00128102	Trial comparisons
Vorinostat vs Placebo: serious adverse events	133 of 329	131 of 329	658	NCT00128102	Trial comparisons
Vorinostat + Bortezomib vs Placebo + Bortezomib: serious adverse events	130 of 315	138 of 320	635	NCT00773747	Trial comparisons
Vorinostat + Paclitaxel + Carboplatin vs Placebo + Paclitaxel + Carboplatin: serious adverse events	63 of 124	45 of 124	248	NCT00473889	Trial comparisons
Idarubicin + Ara-C + Vorinostat (Phase 1) vs Idarubicin + Ara-C + Vorinostat (Phase 2): serious adverse events	0 of 3	3 of 99	102	NCT00656617	Trial comparisons
Arm I (Vorinostat, Paclitaxel, Carboplatin) vs Arm II (Placebo, Paclitaxel, Carboplatin): serious adverse events	29 of 61	10 of 32	93	NCT00481078	Trial comparisons
Vorinostat With Azacitidine, Phase II vs Azacitidine, Phase II: Survival at Day 60	43 of 51	18 of 27	78	NCT00948064	Trial comparisons

1 to 10 of 76

See all 76 comparisons in its trials

Papers from its trials119

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34586085	RESULT	1	PubMed
33478922	RESULT	1	PubMed
32085823	RESULT	1	PubMed
31305287	RESULT	1	PubMed
29373639	RESULT	1	PubMed
28918548	RESULT	1	PubMed
28301423	RESULT	1	PubMed
27025160	RESULT	1	PubMed
26619834	RESULT	1	PubMed
26119093	RESULT	1	PubMed

1 to 10 of 119

See all 119 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL98

GET https://conductscience.org/api/drugs/v1/CHEMBL98/diseases?page=2

API reference For AI assistants